Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Lymphoid 2 Myeloid 1 Dermatologic 1 Classical hematology 1

Conditions

Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

Nivolumab 24 pembrolizumab 22 Ipilimumab 17 Specimen Handling 15 Magnetic Resonance Spectroscopy 9 CTLA-4 Antigen 8 Opdualag 7 relatlimab 6 Cyclophosphamide 6 binimetinib 5 Paclitaxel 5 trametinib 4 fludarabine phosphate 4 fludarabine 4 cemiplimab 4 Carboplatin 4 Biopsy 4 lifileucel 3 dabrafenib 3 atezolizumab 3 X-Rays 3 Taxes 3 Standard of Care 3 Radiotherapy 3 Radiation 3 Pemetrexed 3 Introns 3 Interferon alpha-2 3 Immunoglobulin G 3 Gemcitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Vorinostat × Dermatologic × 30 days × Clear all

NCT02943642 2026-05-18

Resimmune®

Virogen Biotechnology Inc.

Phase 2 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡